MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

The latest financial statement is for the quarter ending 2026-03-31.

Cash Flow Overview

Free Cash flow
-$42,803K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Maturities of marketable securit...
    • Exercise of stock options
    • Stock-based compensation
    • Others
Negative Cash Flow Breakdown
    • Purchases of marketable securiti...
    • Accrued compensation
    • Accretion of discount on marketa...
    • Others

Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Depreciation
---1,036
Net loss
-49,013 -50,216 -40,666 -76,913
Depreciation
537 525 559 1,000
Stock-based compensation
8,715 9,875 8,085 16,792
Accretion of discount on marketable securities, net
1,013 1,483 2,056 4,126
Amortization of right-of-use asset
53 50 47 85
Prepaid expenses and other assets
-3,045 2,715 1,298 3,950
Accounts payable
1,446 -303 -2,132 2,707
Accrued compensation
-6,752 4,432 2,362 -4,420
Accrued other expenses and other liabilities
635 1,436 548 -1,293
Lease liability
-196 -193 -189 -366
Net cash used in operating activities
-42,543 -38,592 -34,776 -70,448
Maturities of marketable securities
---229,118
Purchases of marketable securities
110,152 74,285 66,999 385,942
Sales of marketable securities
3,966 15,932 12,802 38,650
Maturities of marketable securities
108,879 108,188 319,120 -
Purchases of property and equipment
260 73 89 94
Net cash provided by investing activities
2,433 49,762 35,716 -118,268
Proceeds from employee stock purchase plan
-325 0 598
Proceeds from issuance of common stock, net of offering costs
-0 0 187,362
Exercise of stock options
12,173 3,650 1,659 2,494
Net cash provided by financing activities
12,173 3,975 1,659 190,454
Net change in cash and cash equivalents
-27,937 15,145 2,599 1,738
Cash and cash equivalents at beginning of period
61,148 46,003 41,666 -
Cash and cash equivalents at end of period
33,211 61,148 46,003 -
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Exercise of stock options$12,173K Maturities of marketablesecurities$108,879K Sales of marketablesecurities$3,966K Net cash provided byfinancing activities$12,173K Net cash provided byinvesting activities$2,433K Canceled cashflow$110,412K Net change in cashand cash...-$27,937K Canceled cashflow$14,606K Stock-based compensation$8,715K Prepaid expenses andother assets-$3,045K Accounts payable$1,446K Accrued other expensesand other...$635K Depreciation$537K Amortization of right-of-useasset$53K Purchases of marketablesecurities$110,152K Purchases of property andequipment$260K Net cash used inoperating activities-$42,543K Canceled cashflow$14,431K Net loss-$49,013K Accrued compensation-$6,752K Accretion of discount onmarketable securities, net$1,013K Lease liability-$196K

Edgewise Therapeutics, Inc. (EWTX)

Edgewise Therapeutics, Inc. (EWTX)